Keratoprosthesis is the procedure in which a damaged cornea is replaced with an artificial cornea. With the introduction of new materials, such as transparent non-toxic plastics some measure of success for Keratoprosthesis began to be reported. The good results of these new designs have to be attributed to the discovery of antibiotics and steroids, which improved the postoperative management significantly.

A keratoprosthesis, consisting of a central optic held in a cylindrical frame, is an artificial cornea intended to restore vision to patients with severe bilateral corneal disease for whom a corneal transplant is not an option. The keratoprosthesis replaces the cornea that has been removed and is held in place by the surrounding tissue. Various biologic materials are being investigated to improve integration of the prosthetic into the eye.

Presently, there are three Keratoprosthesis with a widespread use in humans: the Boston Keratoprosthesis (B-KPro), the Osteo-Odonto-Keratoprosthesis (OOKP) and the MICOF (Moscow eye Microsurgery Complex in Russia).

For individuals who have corneal blindness and have failed or are not candidates for corneal transplantation who receive a Boston Keratoprosthesis (Boston KPro), osteo-odonto-keratoprosthesis, relevant outcomes are change in disease status, morbid events, quality of life, and treatment-related morbidity. Osteo-odonto-keratoprosthesis is a complex surgical procedure and has been associated with a number of complications, including extrusion of the keratoprosthesis, retinal detachment, and vitreoretinal complications.

The advancements in the field of ophthalmology have continued to grow in developing the new devices and more importantly the improvement of the surgical techniques in preserving the health of the surrounding corneal tissue.

The journal invites different types of articles including original research article, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded directly through mail id: ophthalmologist@eclinicalsci.com or forwarded to the Editorial Office at  https://www.pulsus.com/ophthalmologist-clinical-therapeutic-journal.html

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Colour Art: In a world of black & white journal articles, high-quality full-colour images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy colour reprints of your article on order.

Media Contact:
Sarah Rose
Journal Manager
The Ophthalmologist: Clinical and Therapeutic Journal 
Email: ophthalmologist@eclinicalsci.com
Watsapp:+1-947-333-4405